Latest updates from Engimata

AAPS PharmSci 360 Conference 2023

Date: Oct 21-25, 2023
Location: Orlando, FL

Engimata is honored to present its research titled "A Versatile Room Temperature Stable Lipid Nanoparticle COVID-19 Protein-Based Vaccine." Join us on Monday, October 23, 2023, from 3:30 PM – 4:30 PM ET at Poster Number: M1530-02-08.

Special Note: Our poster has also been chosen for a unique collection and will have an additional presentation on Oct 24th.

 2023 ISV Congress

Date: Oct 22-24, 2023
Location: Virtual Presentation (Main event in Switzerland)
Engimata's research on our lipid nanoparticle COVID-19 vaccine has been accepted for virtual presentation at the International Society for Vaccines (ISV) Congress.

World Vaccine Congress, West Coast 2023

Date: Nov 27-30, 2023
Location: Santa Clara, CA
Engimata is excited to exhibit at this premier event. Join us at the startup pavilion! 

New US Patent Awarded!

On Jan 24, 2023, Engimata was granted US patent US20210299244A1 by the USPTO. This patent covers the use of Engimata's platform adjuvant and the vaccine manufacturing process with nucleic acids.

​​​​​​​View Patent.

AAPS Nanotechnology Community

Kudos to our CEO, Dr. Mitra Mosharraf, who was chosen as Vice Chair for the AAPS Nanotechnology Community. Her term begins in Nov 2023.

AAPS NBC 2024 Announcement

Dr. Mitra Mosharraf is now a Track Chair for the Scientific Programming Committee for the 2024 AAPS NBC.
Aug 15, 2022

Engimata has moved to a new location

We are now located in Livermore, CA.
Aug 10, 2022

Research presentation at the 2022 Colorado Protein Stability Conference

Engimata’s breakthrough research on “A versatile room temperature stable lipid nanoparticle COVID-19 protein-based vaccine”. was presented at the 2022 Colorado Protein Stability Conference in Breckenridge, Colorado on Aug 10th by Dr. Mitra Mosharraf. Other co-authors were Dr. Aryo Sorayya and Dr Rajiv Nayar.  
March 22, 2022

Patent Granted

Engimata is proud to announce that it was granted a US patent for its COVID-19 vaccine.
This patent is a step forward towards a thermostable COVID-19 vaccine which can be distributed at room temperature. It is also the second patent that Engimata received for its vaccine adjuvant platform.

Patent: Mosharraf, M., Sorayya, A., and Nayar, R., Immunogenic Composition Forming a SARS-COV-2 Vaccine, and a method for its manufacture, US Patent 11278617.Granted March 22, 2022.
For any inquiries, please contact us.
Dec 24, 2021

Pleasanton Honors Engimata as one of the Economic Drivers for 2021

The Pleasanton Chamber of Commerce and the City of Pleasanton have joined in recognizing three local businesses as economic drivers for 2021: Engimata, a biotech company involved in the production of vaccines; IrisVision Global, which is developing wearable devices for the visually impaired; and Paxon Energy & Infrastructure, a planning, training and support services company for the oil, gas and utility industries.
Jul 12, 2021

Engimata featured by the Pleasanton Chamber of Commerce and City of Pleasanton

The Chamber's Business Connection newsletter is a bi-montly publication inserted into the Pleasanton Weekly on the first Friday of the odd-numbered months. It features business spotlights on members, a column by the board chair, membership anniversaries, ribbon cuttings and more. 
Engimata Article (PDF)
Business Connection Newsletter
Image and text of Mitra for MIT Sandbox Women EntrepreneursImage and text of Mitra for MIT Sandbox Women Entrepreneurs
Nov 12, 2020

Engimata Founder featured by MIT Sandbox

"Dr. Mitra Mosharraf MBA ’20 CEO of Engimata, Inc. is working to improve vaccine efficiency and enhance vaccine stability. Advice to women entrepreneurs: “Do not be afraid to fail. Failure is just a new starting point that helps us grow until we find the right path.”
Original Post
Engimata LogoEngimata Logo
Aug 28, 2020

A freeze-dried COVID-19 vaccine to improve the immunization supply chain

There is an urgent need for a COVID-19 vaccine. Currently, multiple COVID-19 vaccines are in various stages of development, with Moderna, Pfizer, Sanofi, Johnson & Johnson and AstraZenecca at the frontline. Both Moderna and Pfizer are developing mRNA vaccines that must be stored and transported at -70 °C or -20 °C. This greatly limits their distribution throughout the world because of the complicated and expensive supply chain needed to distribute these vaccines*.

Engimata has focused on development of vaccines that can be transported and stored outside the cold supply chain. We have recently developed a thermostable COVID-19 vaccine that, unlike other vaccines being developed, does not require a complicated cold-chain for transportation and distribution.
Vaccine wastage in the supply chain due to temperature fluctuations is a major problem for current vaccines and costs the government and WHO billions of dollars every year. In order to combat COVID-19, it is crucial to overcome transportation barriers and distribute a vaccine across the world.